Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Soluble Factors Correlated with High-Grade Cytokine Release Syndrome (CRS): A Comparison of Subcutaneous (SC) Versus Intravenous (IV) Delivery of Alnuctamab (ALNUC; BMS-986349; CC-93269) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Isaac W. Boss, Ethan Thompson, Allison M. Gaudy, Minh Diem Vu, Colin D. Godwin, Michael R. Burgess, Sandy W. Wong, Luciano J. Costa

Blood (2022) 140 (Supplement 1): 7116–7117.

https://doi.org/10.1182/blood-2022-163192

Published: 2022

Journal Articles

Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study

Blood (2022) 140 (Supplement 1): 400–402.

https://doi.org/10.1182/blood-2022-159009

Published: 2022

Journal Articles

A Phase 1/2 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm

Colin D. Godwin, Megan Othus, Mary-Elizabeth M. Percival, Paul C. Hendrie, Bart L. Scott, Jacob S. Appelbaum, Anna B. Halpern, Vivian G. Oehler, Johnnie J. Orozco, Sioban B. Keel, Janis L. Abkowitz, Jason P. Cooper, Ryan D. Cassaday, Kaysey F. Orlowski, Anise J. Marshall, Clarisa N. Brown, Elihu H. Estey, Roland B. Walter

Blood (2021) 138 (Supplement 1): 34.

https://doi.org/10.1182/blood-2021-151658

Published: 2021

Journal Articles

Oral Ixazomib in Untreated Follicular Lymphoma Permits COVID-19 Vaccine Response and Its Efficacy Is Associated with Clinical Factors and Gene Expression Signatures

Solomon A. Graf, Ryan C. Lynch, Chaitra S. Ujjani, Ted A Gooley, David G. Coffey, Andrew J. Cowan, Stephen D. Smith, Mazyar Shadman, Edus H. Warren, Edward Libby, Colin D. Godwin, Alexander L Greninger, Jonathan R. Fromm, Ajay K Gopal

Blood (2021) 138 (Supplement 1): 1363.

https://doi.org/10.1182/blood-2021-153168

Published: 2021

Journal Articles

Targeting the Membrane-Proximal C2-Set Domain of CD33 for Improved CD33-Directed CAR T Cell Therapy

Salvatore Fiorenza, George S. Laszlo, Tinh-Doan Phi, Margaret C. Lunn, Delaney R. Kirchmeier, Colin D. Godwin, Erik L. Kimble, Cameron J. Turtle, Roland B. Walter

Blood (2021) 138 (Supplement 1): 2776.

https://doi.org/10.1182/blood-2021-149642

Published: 2021

Journal Articles

Acute myeloid leukemia measurable residual disease detection by flow cytometry in peripheral blood vs bone marrow

Colin D. Godwin, Yi Zhou, Megan Othus, Mallette M. Asmuth, Carole M. Shaw, Kelda M. Gardner, Brent L. Wood, Roland B. Walter, Elihu H. Estey

Blood (2021) 137 (4): 569–572.

https://doi.org/10.1182/blood.2020006219

Published: 2021

Journal Articles

Multiparameter Flow Cytometry (MFC) of Cerebrospinal Fluid (CSF) from Adults Receiving Hypercvad for Acute Lymphoblastic Leukemia/Lymphoma (ALL) Identifies Patients at Higher Risk of Central Nervous System (CNS) Relapse: A Single-Center Retrospective Analysis

Kelsey-Leigh A Garcia, Philip A. Stevenson, MS, Sindhu Cherian, MD, Christen N. Martino, NP, Andrei R Shustov, MD, Pamela S. Becker, MDPhD, Mary-Beth M. Percival, MD, Vivian G. Oehler, MD, Anna B. Halpern, MD, Roland P Walter, MDPhD, Johnnie Orozco, MD, Colin D. Godwin, MDMPhil, Sioban Keel, MD, Elihu H. Estey, MD, Ryan D. Cassaday, MD

Blood (2020) 136 (Supplement 1): 28–30.

https://doi.org/10.1182/blood-2020-137780

Published: 2020

Journal Articles

Ixazomib-Rituximab in Untreated Indolent B-NHL: An Effective, Very Low Toxicity Regimen

Solomon A. Graf, MD, Ryan C. Lynch, MD, Ted A Gooley, PhD, Chaitra S. Ujjani, MD, Peter Wilcox, Sabrina Wilcox, David G. Coffey, MD, Andrew J. Cowan, MD, Stephen D. Smith, MD, Mazyar Shadman, MDMPH, Edus H. Warren, MD PhD, Edward Libby, MD, Colin D. Godwin, MDMPhil, Ryan D. Cassaday, MD, Jonathan R. Fromm, MD PhD, Ajay K. Gopal, MD

Blood (2020) 136 (Supplement 1): 4.

https://doi.org/10.1182/blood-2020-137226

Published: 2020

Journal Articles

Interaction of Remission Status and Cause of Death in Acute Myeloid Leukemia

Mallette M. Asmuth, MD, Anna B. Halpern, MD, Megan Othus, PhD, Emily Huebner, MS, Carole M. Shaw, BA, Kelda Gardner, PA-C, Elihu H. Estey, MD, Roland B. Walter, MDPhDMS, Colin D. Godwin, MDMPhil

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-142730

Published: 2020

Journal Articles

Comparison of Acute Myeloid Leukemia Measurable Residual Disease Detection By Flow Cytometry in Peripheral Blood and Bone Marrow

Colin D. Godwin, MDMPhil, Yi Zhou, MD PhD, Megan Othus, PhD, Carole M. Shaw, BA, Kelda M. Gardner, PA-C, Brent L Wood, MD PhD, Roland B. Walter, MD PhD MS, Elihu H. Estey, MD

Blood (2019) 134 (Supplement_1): 2729.

https://doi.org/10.1182/blood-2019-127128

Published: 2019

Journal Articles

Additional Cytotoxic Chemotherapy Is Unlikely to Eliminate Measurable Residual Acute Myeloid Leukemia (AML)

Jacob Appelbaum, MD PhD, Anisha Loeb, BA, Kelda Gardner, PA-C, Carole M. Shaw, BA, Paul C. Hendrie, MD PhD, Colin D. Godwin, MDMPhil, Mary-Elizabeth M. Percival, MD, Anna B. Halpern, MD, Bart L. Scott, MD, Vivian G. Oehler, MD, Roland B. Walter, MD PhD MS, Pamela S. Becker, MD PhD, Michael C. Jensen, MD, Elihu H. Estey, MD

Blood (2019) 134 (Supplement_1): 260.

https://doi.org/10.1182/blood-2019-131678

Published: 2019

Journal Articles

Phase 1 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm

Colin D. Godwin, MDMPhil, Megan Othus, PhD, Mary-Elizabeth M. Percival, MD, Bart L. Scott, MD, Pamela S. Becker, MD PhD, Kelda M. Gardner, PA-C, Sioban B. Keel, MD, Tejaswini M. Dhawale, MD, Vivian G. Oehler, MD, Janis L. Abkowitz, MD, Anna B. Halpern, MD, Paul C. Hendrie, MD PhD, Kaysey F. Orlowski, Alice Woo, Elihu H. Estey, MD, Roland B. Walter, MD PhD MS

Blood (2019) 134 (Supplement_1): 3892.

https://doi.org/10.1182/blood-2019-126009

Published: 2019

Journal Articles

A Window Study of Ixazomib in Untreated B-NHL

Solomon A. Graf, MD, Ryan C. Lynch, MD, Chaitra S. Ujjani, MD, David G. Coffey, MD, Andrew J. Cowan, MD, Stephen D. Smith, MD, Mazyar Shadman, MD, Edus H. Warren, MD PhD, Edward N. Libby, III, MD, Colin D. Godwin, MDMPhil, Ryan D. Cassaday, MD, Ted A Gooley, PhD, Jonathan R. Fromm, MD PhD, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 5260.

https://doi.org/10.1182/blood-2019-126153

Published: 2019

Journal Articles

Anti-Apoptotic BCL-2 Family Members Confer Resistance to Calicheamicin-Based Antibody-Drug Conjugate Therapy of Acute Leukemia

Colin D. Godwin, MDMPhil, Olivia M. Bates, BA, Sae Rin Jean, PhD, George S. Laszlo, PhD, Eliotte E. Garling, BA, Mary E. Beddoe, BS, Michael H. Cardone, PhD, Roland B. Walter, MD PhD MS

Blood (2019) 134 (Supplement_1): 2561.

https://doi.org/10.1182/blood-2019-126110

Published: 2019

Journal Articles

Bispecific Anti-CD123 x Anti-CD3 Adaptir™ Molecules APVO436 and APVO437 Have Broad Activity Against Primary Human AML Cells In Vitro

Colin D. Godwin, MD MPhil, Olivia M. Bates, BA, George S. Laszlo, PhD, Rebecca Gottschalk, Michael R. Comeau, Gabriela H. Hoyos, Roland B. Walter, MD PhD

Blood (2017) 130 (Supplement 1): 2639.

https://doi.org/10.1182/blood.V130.Suppl_1.2639.2639

Published: 2017

Journal Articles

Sinusoidal obstruction syndrome following CD33-targeted therapy in acute myeloid leukemia

Colin D. Godwin, George B. McDonald, Roland B. Walter

Blood (2017) 129 (16): 2330–2332.

https://doi.org/10.1182/blood-2017-01-762419

Published: 2017

NARROW

Soluble Factors Correlated with High-Grade Cytokine Release Syndrome (CRS): A Comparison of Subcutaneous (SC) Versus Intravenous (IV) Delivery of Alnuctamab (ALNUC; BMS-986349; CC-93269) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study

A Phase 1/2 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm

Oral Ixazomib in Untreated Follicular Lymphoma Permits COVID-19 Vaccine Response and Its Efficacy Is Associated with Clinical Factors and Gene Expression Signatures

Targeting the Membrane-Proximal C2-Set Domain of CD33 for Improved CD33-Directed CAR T Cell Therapy

Acute myeloid leukemia measurable residual disease detection by flow cytometry in peripheral blood vs bone marrow

Multiparameter Flow Cytometry (MFC) of Cerebrospinal Fluid (CSF) from Adults Receiving Hypercvad for Acute Lymphoblastic Leukemia/Lymphoma (ALL) Identifies Patients at Higher Risk of Central Nervous System (CNS) Relapse: A Single-Center Retrospective Analysis

Ixazomib-Rituximab in Untreated Indolent B-NHL: An Effective, Very Low Toxicity Regimen

Interaction of Remission Status and Cause of Death in Acute Myeloid Leukemia

Comparison of Acute Myeloid Leukemia Measurable Residual Disease Detection By Flow Cytometry in Peripheral Blood and Bone Marrow

Additional Cytotoxic Chemotherapy Is Unlikely to Eliminate Measurable Residual Acute Myeloid Leukemia (AML)

Phase 1 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm

A Window Study of Ixazomib in Untreated B-NHL

Anti-Apoptotic BCL-2 Family Members Confer Resistance to Calicheamicin-Based Antibody-Drug Conjugate Therapy of Acute Leukemia

Bispecific Anti-CD123 x Anti-CD3 Adaptir™ Molecules APVO436 and APVO437 Have Broad Activity Against Primary Human AML Cells In Vitro

Sinusoidal obstruction syndrome following CD33-targeted therapy in acute myeloid leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only